DK1919951T3 - Anti-tnf-alfa-antistoffer og fremgangsmåder til anvendelse - Google Patents

Anti-tnf-alfa-antistoffer og fremgangsmåder til anvendelse Download PDF

Info

Publication number
DK1919951T3
DK1919951T3 DK06774701.4T DK06774701T DK1919951T3 DK 1919951 T3 DK1919951 T3 DK 1919951T3 DK 06774701 T DK06774701 T DK 06774701T DK 1919951 T3 DK1919951 T3 DK 1919951T3
Authority
DK
Denmark
Prior art keywords
ser
gly
tyr
leu
thr
Prior art date
Application number
DK06774701.4T
Other languages
English (en)
Inventor
Katya Mclane
Gopalan Raghunathan
Glen A Evans
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Application granted granted Critical
Publication of DK1919951T3 publication Critical patent/DK1919951T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)

Claims (9)

1. Antistof der er i stand til at binde til TNF-alfa, hvor antistoffet omfatter: (a) et polypeptid omfattende et polypeptid med sekvensen vist i SEQ ID NO: 2; og (b) et polypeptid omfattende et polypeptid med sekvensen vist i SEQ ID NO: 380, hvor antistoffet binder TNF-alfa med affinitet større end den for infliximab som bestemt under anvendelse af et Biacore assay, og hvor infliximab VH-regionen har sekvensen vist i SEQ ID NO: 1 og infliximab VL-regionen har sekvensen vist i SEQ ID NO: 379.
2. Antistof ifølge 1, hvor polypeptidet ifølge krav 1(a) med sekvensen vist i SEQ ID NO:2 har sekvensen vist i SEQ ID NO: 3.
3. Biologisk aktivt fragment af antistoffet ifølge krav 1 eller krav 2.
4. Cellelinje der udtrykker antistoffet ifølge krav 1 eller krav 2 eller det biologisk aktive fragment ifølge krav 3.
5. Cellelinje omfattende en vektor omfattende et polynukleotid der koder for polypeptidet angivet i krav 1(a) eller krav 2 og en vektor omfattende et polynukleotid der koder for polypeptidet angivet i krav 1(b).
6. Cellelinje ifølge krav 5 hvor polynukleotidet der koder for polypeptidet angivet i krav 1 eller krav 2 har sekvensen vist i SEQ ID NO: 191 eller en komplementær sekvens.
7. Cellelinje ifølge krav 5 eller krav 6, hvor polynukleotidet der koder for polypeptidet angivet i krav 1(b) har sekvensen vist i SEQ ID NO: 381 eller en komplementær sekvens.
8. Cellelinjen ifølge et hvilket som helst af kravene 4 til 7 hvor cellelinjen er en HEK293, NSO, SP2/0 eller CHO cellelinje.
9. Farmaceutisk sammensætning omfattende en effektiv mængde af mindst ét antistof ifølge krav 1 eller krav 2 eller af mindst ét biologisk aktivt fragment ifølge krav 3 og en farmaceutisk acceptabel bærer eller diluent.
DK06774701.4T 2005-08-04 2006-07-27 Anti-tnf-alfa-antistoffer og fremgangsmåder til anvendelse DK1919951T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70542705P 2005-08-04 2005-08-04
PCT/US2006/029114 WO2007019064A2 (en) 2005-08-04 2006-07-27 ANTI-TNFα ANTIBODIES AND METHODS OF USE

Publications (1)

Publication Number Publication Date
DK1919951T3 true DK1919951T3 (da) 2015-02-16

Family

ID=37727836

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06774701.4T DK1919951T3 (da) 2005-08-04 2006-07-27 Anti-tnf-alfa-antistoffer og fremgangsmåder til anvendelse

Country Status (9)

Country Link
US (2) US7560108B2 (da)
EP (1) EP1919951B1 (da)
JP (2) JP2009502195A (da)
DK (1) DK1919951T3 (da)
ES (1) ES2535426T3 (da)
PL (1) PL1919951T3 (da)
PT (1) PT1919951E (da)
SI (1) SI1919951T1 (da)
WO (1) WO2007019064A2 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807168B2 (en) 2007-04-10 2010-10-05 Vaccinex, Inc. Selection of human TNFα specific antibodies
CL2010000019A1 (es) * 2010-01-11 2010-06-11 Univ Chile Anticuerpo monoclonal contra el tnf humano y sus fragmentos, secuencias nucleotidicas que lo codifican, vector de expresion y celulas que las contienen, composiciones y kit que comprenden el anticuerpo, uso de los mismos y metodo para su obtencion.
US20140085100A1 (en) 2012-09-25 2014-03-27 Woodstream Corporation Wireless notification system and method for electronic rodent traps
US20140300477A1 (en) 2012-09-25 2014-10-09 Woodstream Corporation Wireless notification systems and methods for electronic rodent traps
AR118191A1 (es) * 2019-02-28 2021-09-22 Celltrion Inc MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa
CN119264230B (zh) * 2024-08-27 2026-04-10 湖南农业大学 一种猪流行性腹泻病毒s1重组蛋白、试剂盒及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698195A (en) 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
EP1857553A1 (en) * 1991-03-18 2007-11-21 New York University Monoclonal and chimeric antibodies specific for human tumor necrosis factor
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
EP0983303B1 (en) * 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
PT1015576E (pt) 1997-09-16 2005-09-30 Egea Biosciences Llc Metodo para a sintese quimica completa e montagem de genes e de genomas
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
AU776910B2 (en) * 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
ATE469176T1 (de) * 2001-11-12 2010-06-15 Merck Patent Gmbh Modifizierter anti-tnf antikörper
US7101978B2 (en) * 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
US20040131613A1 (en) * 2003-01-08 2004-07-08 Watkins Jeffry D. TNF-alpha binding molecules
US6832823B1 (en) * 2003-05-30 2004-12-21 Hewlett-Packard Development Company, L.P. Disabling ink ejection elements to decrease dot placement artifacts in an inkjet printhead

Also Published As

Publication number Publication date
ES2535426T3 (es) 2015-05-11
US7560108B2 (en) 2009-07-14
JP2009502195A (ja) 2009-01-29
WO2007019064A3 (en) 2009-04-16
PT1919951E (pt) 2015-03-04
PL1919951T3 (pl) 2015-07-31
US20070092518A1 (en) 2007-04-26
US20090012266A1 (en) 2009-01-08
JP5261602B2 (ja) 2013-08-14
JP2013034481A (ja) 2013-02-21
EP1919951A4 (en) 2011-01-19
EP1919951B1 (en) 2015-01-28
HK1117849A1 (en) 2009-01-23
WO2007019064A2 (en) 2007-02-15
US7790871B2 (en) 2010-09-07
EP1919951A2 (en) 2008-05-14
SI1919951T1 (sl) 2015-05-29

Similar Documents

Publication Publication Date Title
JP5623401B2 (ja) 抗ｉｌ−１２／ｉｌ−２３抗体
JP6126991B2 (ja) ヒトｉｉ型コラーゲンに結合する抗体
KR101836217B1 (ko) Ｉｌ-１７ａ 길항제
TWI482630B (zh) 抗人類ｔｗｅａｋ抗體及其用途
US20130171146A1 (en) Dual-specific il-1a/ il-1b antibodies
WO2011103701A1 (zh) 全人源抗TNF-α单克隆抗体、其制备方法及用途
AU2016369307A1 (en) Multi-specific antibody molecules having specificity for TNF-alpha, IL-17A and IL-17F
CN106573053A (zh) 干扰素α和ω抗体拮抗剂
JP5261602B2 (ja) 抗ＴＮＦα抗体および使用方法
CN115461370B (zh) St2抗原结合蛋白
WO2021023274A1 (zh) 人源化抗TNFα抗体及其用途
KR20140062127A (ko) 견화(犬化) 항체 및 그의 제조방법
JP2004536605A (ja) インターロイキン１β抗体
CN112480254B (zh) 抗人白细胞介素-33受体的抗体及其制备方法和应用
CN118638234B (zh) 抗bdca2抗体及其制备方法和应用
HK1117849B (en) Anti-tnf-alpha antibodies and methods of use
CN118019760A (zh) 抗IL-1-β抗体
CN120230206A (zh) 抑瘤素M受体β结合抗体及其用途
HK1186195B (en) Antibodies against human tweak and uses thereof
ZA200602015B (en) Antibodies against interleukin-1receptor and uses thereof